Best COVID-19 drug play ready to pop! $AVIR

Thesis I believe $AVIR (Atea Pharma) to be the most under-rated COVID-19 related biotech stock in the market to date. Their interim analysis data relating to treatment of COVID-19 is unmatched in the field. With delta wave surging, many countries way behind on vaccinating and healthcare systems set for the toughest winter in living memory the stage is set for Atea's AT-527 to be a worldwide phenomenon. $AVIR is hugely undervalued presently #Ilikethechart. What's the data so far saying? Atea Pharmaceuticals and Roche's oral anti-viral drug for COVID-19, AT-527, reduced viral loads in hospitalized patients, according to interim phase 2 data published June 2021. Interim virology results indicated that AT-527 rapidly reduced viral load levels. At Day 2, patients receiving AT-527 experienced a 0.7 log10 (80%) greater mean reduction from baseline viral load as compared to placebo. A sustained difference in viral load reduction was maintained through Day 8. When evaluating a strict RT-qPCR threshold of 500 copies/mL with no detectable ribonucleic acid (RNA) virus, the AT-527 arm achieved SARS-CoV-2 clearance as early as Day 2 (in 6% of patients), Day 8 (in 7% of patients) Day 10 (in 33% of patients), and Day 12 (in 31% of patients) compared to 0% of patients in the placebo arm at the same timepoints. By Day 14 (last viral sampling study day) approximately 47% of patients in the AT-527 arm and 22% in the placebo arm had no detectable RNA virus (TND). AT-527 was safe and well-tolerated in the study. And what's next? Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 (MORNINGSKY) has a COMPLETION DATE of 3rd August 2021..... that's just around the corner my fellow apes. (https://clinicaltrials.gov/ct2/show/NCT04889040 ) "I don't care for fundamentals show me a chart I can draw shit on" You'll see from the chart things are looking promising for a pop on a few accounts: Gently wedging up against R of IPO price Huge volume below IPO price (May onwards) indicates big players loading up in consolidation TR (Volume Price Action Theory) Multiple tests of 26-27 area Last 9 days above 50 day EMA Profit target 60+ minimum TL;DR - Atea ($AVIR) is consolidating for explosion.... Get in now whilst the big players are and ride it with them. #Ilikethechart

Scouted Idea

We scour the net for great ideas, so you don't have to

Original Post

DrBenC

Jul 30, 2021

-69.90%

Change % Since Posting

-17.09

Change Since Posting

24.45

Price When Posted

AVIR

Atea Pharmaceuticals, Inc.

7.36

-0.13

-1.74%

Current Price

Is this your Reddit account?

Claim this username to collect earnings from this post, and the portfolio!

Best COVID-19 drug play ready to pop! $AVIR

bullish

Thesis

I believe $AVIR (Atea Pharma) to be the most under-rated COVID-19 related biotech stock in the market to date. Their interim analysis data relating to treatment of COVID-19 is unmatched in the field. With delta wave surging, many countries way behind on vaccinating and healthcare systems set for the toughest winter in living memory the stage is set for Atea's AT-527 to be a worldwide phenomenon. $AVIR is hugely undervalued presently #Ilikethechart.

What's the data so far saying?

Atea Pharmaceuticals and Roche's oral anti-viral drug for COVID-19, AT-527, reduced viral loads in hospitalized patients, according to interim phase 2 data published June 2021.

Interim virology results indicated that AT-527 rapidly reduced viral load levels. At Day 2, patients receiving AT-527 experienced a 0.7 log10 (80%) greater mean reduction from baseline viral load as compared to placebo. A sustained difference in viral load reduction was maintained through Day 8. When evaluating a strict RT-qPCR threshold of 500 copies/mL with no detectable ribonucleic acid (RNA) virus, the AT-527 arm achieved SARS-CoV-2 clearance as early as Day 2 (in 6% of patients), Day 8 (in 7% of patients) Day 10 (in 33% of patients), and Day 12 (in 31% of patients) compared to 0% of patients in the placebo arm at the same timepoints. By Day 14 (last viral sampling study day) approximately 47% of patients in the AT-527 arm and 22% in the placebo arm had no detectable RNA virus (TND).

AT-527 was safe and well-tolerated in the study.

And what's next?

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 (MORNINGSKY) has a COMPLETION DATE of 3rd August 2021..... that's just around the corner my fellow apes. (https://clinicaltrials.gov/ct2/show/NCT04889040 )

"I don't care for fundamentals show me a chart I can draw shit on"

You'll see from the chart things are looking promising for a pop on a few accounts:

Gently wedging up against R of IPO price
Huge volume below IPO price (May onwards) indicates big players loading up in consolidation TR (Volume Price Action Theory)
Multiple tests of 26-27 area
Last 9 days above 50 day EMA

Profit target

60+ minimum

TL;DR - Atea ($AVIR) is consolidating for explosion....

Get in now whilst the big players are and ride it with them.

#Ilikethechart